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Abstract
The application of a rapid and direct proteotyping approach with which to identify the gene origin of viral antigens in a
reassortant influenza strain is demonstrated. The reassortant strain, constructed for a vaccine against type A 2009 H1N1
pandemic influenza, contains genes derived from a wild-type pandemic strain (A/California/7/2009) and an egg adapted
high-growth strain (denoted NYMC X-157) derived from an earlier A/Puerto Rico/8/34 strain. The proteotyping approach
employs modern proteomics methods and high resolution mass spectrometry to correctly establish that the genes of the
surface antigens, hemagglutinin and neuraminidase, are derived from the A/California/7/2009 strain while those for
nucleoprotein and matrix protein M1 antigens are derived from the NYMC X-157 strain. This is achieved for both gel-
separated antigens and those from a whole vaccine digest. Furthermore, signature peptides detected in the mass spectra of
the digested antigens enable the engineered reassortant strain to be identified as a type A virus of the H1N1 subtype in
accord with earlier studies. The results demonstrate that proteotyping approach provides a more direct and rapid approach
over RT-PCR with which to characterize reassortant strains of the influenza virus at the molecular protein level. Given that
these strains pose the greatest risk to human and animal health and have been responsible for all human pandemics of the
20th and 21st centuries, there is a vital need for the origins and evolutionary history of these strains to be rapidly
established.
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Introduction
In addition to antigenic drift [1], caused by errors in viral
replication and the antigenic pressure applied to the surface
hemagglutinin and neuraminidase antigens by the immune
response, the evolution of the influenza virus is shaped by the
reassortment process [2,3]. The virus has a high potential to
reassort due to the segmented nature of its genome that consists of
eight negative-strand RNA segments. When two different strains
of influenza virus co-infect the same cell, progeny viruses
(reassortants) are created that contain genes derived from each
parent. Genetic reassortment among influenza viruses occurs
naturally and plays an important role in viral epidemiology and
pathogenicity [4].
All of the pandemics of the 20th and 21st century have resulted
from reassorted type A influenza viruses of the H1N1, H2N2, and
H3N2 subtypes [5]. The most recent 2009 influenza pandemic
strain originated around 1998 when the swine influenza viruses
reassorted with a human type A (H3N2) influenza virus and an
avian influenzavirusof an unknown subtype. Thisproduced a triple
reassorted H3N2 virus in swine populations throughout North
America [6]. Subsequent reassortment with a H1N1 swine strain of
the virus resulted in the generation of the triple reassorted swine A
(H1N1) that caused the 2009 H1N1 influenza pandemic [6].
There is increasing concern that the 2009 pandemic strain
could reassort with seasonal strains to produce a deadly new strain
of the virus. In the southern hemisphere, the pandemic strain
dominated the influenza season providing an opportunity for
reassortment with later seasonal strains [7]. Of particular concern
is if the pandemic strain acquires the neuraminidase gene from
seasonal influenza and establishes some resistance to anti-viral
inhibitors [8]. The ability to rapidly characterize reassortant
strains of the virus and assess the origin of the genes that encode
viral antigens is therefore of vital importance.
The influenza virus is traditionally characterized at the
molecular level using the reverse transcriptase polymerase chain
reaction (RT-PCR). The isolation of viral RNA is followed by
reverse transcription of prescribed gene segments to generate
cDNA, their subsequent amplification using primers to these
targets, and the detection and/or sequencing of the amplificons.
Strategies to characterize reassortant strains of the virus have been
developed [9,10], but since gene reassortment appears to be
random, full characterization of a progeny virus requires the
sequencing of part or all of the eight genes, a process that is quite
laborious and can take several days to achieve.
A rapid and direct proteotyping approach with which to both
type and subtype influenza viral strains employing proteomics
methods and high resolution mass spectrometry has recently been
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signature peptide ion representing a conserved sequence of a viral
antigen that is also unique in mass, within a few part-per-million
(ppm), when compared to the in silico digestion products of all
influenza antigens from all hosts, is sufficient to be able to
confidently type and subtype strains of the influenza virus. It
complements related studies that have employed proteomics
methods and mass spectrometry to characterise the antigenicity of
the influenza virus [15–18]. More recently, it has been shown that
the proteotyping approach can distinguish seasonal from pandemic
type A H1N1 influenza strains [19] and also assign the lineage of
human strains of type A H1N1 and type B influenza virus [20].
Given the pandemic potential of reassorted strains of influenza
virus, this study demonstrates that the origin of the genes encoding
the viral antigens within reassorted strains can also be rapidly and
unequivocally determined using this proteotyping strategy.
Establishing the gene origin of reassorted pandemic strains of
the virus is essential to the design and production of vaccines
against such strains and to monitor their evolutionary history. This
is illustrated a strain formed by the reassortment of a wild-type and
an egg adapted high-growth strain that was constructed for a
vaccine that has been administrated against 2009 pandemic H1N1
influenza virus.
Results and Discussion
The PanVax H1N1 vaccine, produced against pandemic 2009
H1N1 influenza (‘‘swine flu’’), contains a single strain of influenza
virus without adjuvant. The vaccine was prepared from a classical
genetic reassortment of a wild-type strain (A/California/07/2009)
and an egg adapted high-growth strain (NYMC X-157) derived
from an earlier A/Puerto Rico/8/34 strain. The reassorted
vaccine strain thus contains genes that originated from both source
strains (Figure 1).
The major antigens derived from the vaccine strain were
partially separated by SDS-PAGE (Figure 2). The most prominent
bands were detected for nucleoprotein and matrix M1 protein in
accord with their higher copy numbers per virion, as evident in
our previous studies [18,19]. The matrix protein constitutes some
40% of the total viral protein while the hemagglutinin and
neuraminidase surface antigens constitute only 25% and 5% of all
viral protein respectively.
The hemagglutinin antigen appears as a partially resolved, faint
band above that of nucleoprotein at a molecular weight of
approximately 65 kDa. The high resolution MALDI mass
spectrum of this band is shown in Figure 3. Eleven of the tryptic
peptides detected (labelled in bold) are associated with the
hemagglutinin antigen. With the exception of one peptide, all
are unique in sequence to those derived from the A/California/7/
2009 strain correctly establishing it as the origin of the
hemagglutinin gene within the reassorted vaccine strain. A single
peptide at m/z 2030.0213 comprises HA residues 120–136 which
has an identical sequence in both the A/California/7/2009 and
A/Puerto Rico/8/34 strain.
The MALDI spectrum also enables the strain to be identified as
the vaccine strain, over the originating A/California/7/2009
strain, due to the detection of a dominant peptide ion of unique
sequence that comprises HA residues 226–236 (TFKPEIAIRPK)
at m/z 1299.7778. The threonine residue at position 226 replaces
lysine in the original A/California/7/2009 strain and thus
increases the peptide’s mass by 27 units.
The high resolution MALDI mass spectrum of the upper
neuraminidase band of Figure 2 is shown in Figure 4. This
spectrum exhibits 10 tryptic peptides derived from the neuramin-
Figure 1. Representation of the gene origin of the reassortant
(NYMC X-181) strain used to vaccinate against 2009 pandemic
H1N1 influenza.
doi:10.1371/journal.pone.0015771.g001
Figure 2. SDS-PAGE gel showing the viral antigens neuramin-
idase, hemagglutinin H1 subunit, nucleoprotein and matrix M1
protein of the reassortant (NYMC X-181) strain aside molecular
weight markers.
doi:10.1371/journal.pone.0015771.g002
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strain to be identified as the origin of the NA gene. In this case,
two peptides comprising residues HA 151–156 and 108–118 at m/
z 793.3945 and 1190.6883 share a common sequence and mass
with the A/Puerto Rico/8/34 strain. The remaining 8 are unique
to the A/California/7/2009 strain.
Both surface antigens, hemagglutinin and neuraminidase, are
identified to be derived from the A/California/7/2009 strain. The
reverse is true in the case of the nucleoprotein (NP) and matrix
protein 1 (M1). The tryptic peptides that were detected following
the digestion of the NP and M1 bands, at approximately 65 and
30kDa (in Figure 2), are shown in Tables S1 and S2 respectively.
The larger number of peptide ions detected for these antigens is
associated with the higher copy numbers of these antigens per
virion reflected in the more predominant bands on the gel.
In the case of the nucleoprotein antigen, the detected peptides
represent 59% of the total sequence. While some NP peptides
share a common sequence in the nucleoprotein sequence of the A/
California/7/2009 and A/Puerto Rico/8/34 strains, the majority
(shaded) are unique in sequence to the A/Puerto Rico/8/34 strain
(38% coverage) and enable the origin of the gene in the reassortant
strain to be correctly assigned to this strain.
Of the 39 NP peptides detected, three represent type A
signature peptides for this antigen [12] at m/z 672.4422, 961.4442
and 1067.5194 enable the reassortant virus strain to be
unambiguously assigned as a type A strain. Furthermore, two
H1N1 subtype specific signature peptides are detected at m/z
1344.5345 and 2036.9376 [12]. The latter represents the modified
form of the peptide comprised of NP residues 326–342 in which
the methinione residue is oxidised and the cysteine residue is
carbamidomethylated due to the reduction and alkylation of
cysteine residues prior to tryptic digestion.
In the case of the matrix protein 1 (M1), 29 tryptic peptides are
detected spanning 77% of the total protein sequence. Those
shaded have a sequence, and thus mass, that is unique to the A/
Puerto Rico/8/34 strain. Their detection enables the origin of the
matrix protein gene to be established as the A/Puerto Rico/8/34
strain. Eight of the tryptic peptides (labelled at their sequence in
Table S2) represent or contain type A matrix M1 protein signature
peptides that further confirm the virus strain type [13].
To establish that the proteotyping approach can also be applied
to identify gene origin in whole virus, without the need to separate
the component viral antigens, a solution of digested whole vaccine
was analyzed. The MALDI mass spectrum of the tryptic products
generated is shown in Figure 5. Although fewer peptide ions are
detected, due both to the steric constraints imposed by the virion
that impedes digestion and the competitive ionisation processes
when large mixtures of peptides are analysed, all four antigens are
represented in the spectrum. Among the hemagglutinin peptides
detected, the peptide comprised of residues 226–236 (at m/z
1299.7739) described above establishes the origin of the HA gene
to be the A/California/7/2009 strain. A sole NA peptide at m/z
805.4543 comprises residues 112–118 of the antigen also has a
sequence (GDVFVIR) unique to the A/California/7/2009 strain.
Figure 3. High resolution MALDI mass spectrum of the tryptic digest of the hemagglutinin H1 antigen (HA) band of Figure 2.
doi:10.1371/journal.pone.0015771.g003
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761.3926, 1067.4601, 1187.6764 and 1344.5319 are all unique to
the A/Puerto Rico/8/34 strain. The M1 peptide detected at m/z
1273.6880 corresponding to residues 164–174 is also of a sequence
that is unique to the reassortant strain. This confirms the A/Puerto
Rico/8/34 strain is the origin of both the matrix and
nucleoprotein, though the reassortant strain and not the
originating strain is that which has been analysed.
Although not detected by SDS-PAGE (Figure 2) due to their
lower levels (100–3000 fold less) per virion, the viral polymerases
(PA and PB) and non-structural proteins (NS) were detected within
the spectrum of the whole vaccine digest (Figure 5). For examples,
ions detected at m/z 965.4410, 1229.5770 and 1278.6437 are
associated with residues 577–583, 20–29 and 246–256 of
polymerase PA while ions at m/z 779.4411, 877.4852 and
939.4729 are associated with residues 572–577 and 472–479 of
polymerase PB1, and residues 598–604 of polymerase PB2,
respectively. However, since these proteins are highly conserved
among strains and share a 96% sequence identity and 99%
sequence homology across the A/California/7/2009 and A/
Puerto Rico/8/34 strains they provide little to no value for
establishing the origin of their genes.
The application of a proteotyping approach, previously applied
to the rapid and direct identification of the type, subtype and
lineage of influenza strains, has been successfully utilized here to
identify the origin of genes within a reassorted strain of the
influenza virus. Given the these reassorted strains pose the greatest
risk to human and animal health and have been responsible for all
past human pandemics of the 20th and 21st centuries, the ability
to rapidly and reliably establish the origins and evolutionary
history of such strains at a molecular level is of paramount
importance. In the case of whole virus digests, the approach is
limited only by the time required for proteolytic digestion, a
process that can be accelerated using microwave irradiation [21].
Due to the nature of the MALDI target plate, hundreds (typically
100–384) of virus samples, digested in parallel, can be applied to a
single plate with a mass spectrum for each sample acquired within
fractions of a seconds to a few minutes. The approach does require
access to a high resolution mass spectrometer of some considerable
cost (typically $US500K-1M) but has broader applicability to
other biopathogens that threaten human and animal health.
Materials and Methods
Influenza virus reassortment strain
The PanVax H1N1 vaccine was donated by CSL Biotherapies,
CSL Limited (Parkville, Victoria, Australia) and used without
further purification. The vaccine is formulated at a dose
corresponding to 30 ng/mL of hemagglutinin. It contains strain
NYMC X-181, a reassortant strain comprised of genomic
segments coding for the HA, NA and PB1 antigens which were
derived from the pandemic (H1N1) 2009 strain A/California/7/
2009. The remaining segments are derived from the A/Puerto
Rico/8/34 (H1N1) strain. Translated protein sequences were
derived from GenBank [22] via the Influenza Virus Resource [23]
with the following accession numbers: HA ACV82259 (reassor-
tant), ACP44189 (A/California/7/2009); NA ACV82260 (reas-
sortant), ACT36688 (A/California/7/2009); NP ADE29086
Figure 4. High resolution MALDI mass spectrum of the tryptic digest of the neuraminidase antigen (NA) band of Figure 2.
doi:10.1371/journal.pone.0015771.g004
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(reassortant), ABD77676 (A/Puerto Rico/8/34).
Viral antigen recovery
The PanVax H1N1 vaccine (120 mL containing 10 ng of total
viral antigen) was subjected to SDS-PAGE using a Bio-Rad
TetraCell gel box attached to a Bio-Rad Powerpac 300 power
supply (Bio-Rad, Hercules, CA, USA). The vaccine was
concentrated to approximately 10 mL by a vacuum concentrator
(Labconco Corporation, Kansas City, MI, USA) and diluted in 1:2
with Laemmli buffer containing 100mM Tris-HCl (pH 6.8), 10%
(v/v) glycerol, 2% (w/v) SDS, 3.3% (v/v) 2-mercaptoethanol and
0.02mg/ml Bromophenol Blue. The sample was then heated for
10 min at 97uC in an Eppendorf Thermomixer 5468 (Eppendorf,
Hamburg, Germany). A Precision Plus protein standard solution
(Bio-Rad, Hercules, CA, USA) (15 mL) was loaded alongside the
vaccine sample on a polyacrylamide gel (12.5% separating and 5%
stacking gels). SDS-PAGE was performed in a buffered solution
containing 25 mM Tris-HCl, 192 mM glycine and 0.1% (w/v)
SDS (pH 7.5) at 15 mA for 1.5 hours. The separated bands were
visualised by a Coomassie Brilliant Blue solution (0.25% w/v
Coomassie Brilliant Blue, 45% v/v methanol and 10% v/v glacial
acetic acid). The gel was then destained in an aqueous solution
containing 40% v/v methanol and 7% v/v glacial acetic acid for
1 hour and subsequently in an aqueous solution containing 5% v/
v methanol and 7% v/v glacial acetic acid overnight. The gel was
scanned using a Bio-Rad, GS-800 densitometer (Bio-Rad,
Hercules, CA, USA).
In-gel tryptic digestion
The bands containing hemagglutinin, neuraminidase, nucleo-
protein and matrix M1 protein were manually excised and
reconstituted in a solution of 25 mM ammonium bicarbonate
(NH4HCO3) in 50% v/v acetonitrile (ACN) at 37uC. The cysteine
residues were reduced with dithiothreitol (DTT) (10 mM in
50 mM NH4HCO3 pH 8.5) for 30 min at 56uC and alkylated
with iodoacetamide (55 mM iodoacetamide in 50 mM
NH4HCO3 pH 8.5) for 20 min at room temperature with
protection from ambient light. Excess iodoacetamide was removed
by washing with ACN (36350 mL) and the gel pieces were dried in
a vacuum concentrator (Labconco Corporation, Kansas City, MI,
USA). In-gel tryptic digestion of the hemagglutinin, neuramini-
dase, nucleoprotein and matrix M1 protein was performed using
13 ng?mL
21 of modified trypsin (Roche Diagnostics GmbH,
Mannheim, Germany) overnight at 37uC in a digestion buffer
containing 25 mM NH4HCO3, 10% ACN and 3.4 mM octyl-b-
D-glucopyranoside. The resulting peptides were extracted by
repeated sonication in 60% ACN containing 0.1% trifluoroacetic
acid (TFA). The extracted peptides were dried completely in a
vacuum concentrator and redissolved in a 25 mM NH4HCO3
solution.
Whole vaccine tryptic digestion
A suspension corresponding to 35mg of the whole virus was
concentrated to near dryness in a vacuum concentrator and
redissolved in 50mL digestion buffer (50 mM NH4HCO3, 10%
ACN and 2 mM DTT, pH 7.5). Sequence-grade modified trypsin
Figure 5. High resolution MALDI mass spectrum of the tryptic digest of the whole PanVax H1N1 vaccine.
doi:10.1371/journal.pone.0015771.g005
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13ng?mL
21 and the solution was incubated overnight at 37uC.
High resolution MALDI mass spectrometry
Each digested solution (1 mL) was diluted with in a solution
(3 mL) of a MALDI matrix (2 mg?mL
21 a-cyano-4-hydroxycinna-
minic acid in 50% ACN containing 0.1% TFA). The mixed
analyte and matrix solution (1 mL) was spotted onto a MALDI
sample plate (MTP AnchorChip
TM 400/384 TF, Bruker Dal-
tonics, Billerica, MA, USA) and dried by evaporation in air.
MALDI FT-ICR mass spectra were recorded on a 7T Bruker
APEX-Qe instrument (Bruker Daltonics, Billerica, MA, USA) in
the positive ion mode. Ions released with between 25–200 laser
shots (at 5% laser power) from the MALDI plate, held at 400V,
were accumulated above the plate for 0.2 sec, stored in the
hexapole for 1.0 sec, and then passed to the FT-ICR cell in
1.0 msec using a side kick voltage of 0 V and an offset of 21.5 V.
15–32 scans were acquired and averaged into a single mass
spectrum. Spectra were acquired with 1M data points using a
broadband excitation across a mass range of m/z 404–4000. A
mass resolution of over 100,000 (FWHM) at m/z 1296 was
typically achieved. The instrument was mass calibrated with an
external mixture of peptides comprising Angiotensin I, adreno-
corticotropic hormone (ACTH) fragments comprising residues 1–
17, 7–38 and 18–39, and a synthetic hemagglutinin antigen
derived peptide. Mass spectra were processed using the Data
Analysis v3.4 software (Billerica, MA, USA) and, in some cases,
internally mass calibrated using identified peptide ions in each
spectrum derived from the viral proteins or tryptic autolysis
products. Peptides were identified through a search of the NCBI
non-redundant protein database using the Mascot Peptide Mass
Fingerprint algorithm [24] with the following constraints:
taxonomy – viruses, modifications - oxidation (M), Gln/Glu to
Pyro-Glu, and carbomidomethyl-cysteine, and a peptide tolerance
of +/25 ppm. These searches were performed in conjunction with
manual assignments of peptide ions using theoretical monoisotopic
mass values for tryptic digest products of database antigen
sequences generated by the MS-Fit algorithm [25] using the same
criteria. Mass accuracies of better than 5ppm were routinely
achieved for all ions detected.
Supporting Information
Table S1 Nucleoprotein derived peptides from the tryptic
digestion of the NP band of the NYMC X-181 reassortant strain
as detected by MALDI-MS.
(DOC)
Table S2 Matrix M1 protein derived peptides from the tryptic
digestion of the M1 band of the NYMC X-181 reassortant strain
as detected by MALDI-MS.
(DOC)
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